Speaker: Li Hui, PhD, MD, Scientific Director of Biocytogen Boston Corp
To human or to humanize? This is a great question for therapeutic antibody discovery. Human antibodies that are generated from immunoglobulin transgenic mice have been proved to be successful due to the in vivo natural selection, affinity maturation of antibody secreting B cells. To meet the expanding needs of the therapeutic antibody market, Biocytogen established first and second generation of immunoglobulin humanized mouse platforms: RenMab, RenMab KO and RenLite.
